News for Novartis AG (NVSN.MX)

U.S. stock futures rose Monday night even as Wall Street had a rough start to the week, amid growing concerns regarding the Federal Reserve's independence, and President Donald Trump's repeated attacks on Fed Chair Jerome Powell for not cutting interest rates.

Market Analysis by covering: Novartis AG ADR, The Lovesac Company, Schrodinger Inc, Certara Inc. Read 's Market Analysis on Investing.com

The moves, announced Monday in the Federal Register, are a precursor to imposing tariffs and threaten to broaden the president’s sweeping US trade war.

\nRaised forecast due to strong sales of blockbuster medicines for heart disease and psoriasis.Stock saw its biggest boost in nine months.Risks include patent ex

Donald Trump has — for now — backed off of his steepest tariff increases. But with other duties still in place, doing business in the US is about to get costlier for EU companies.

Summary: Novartis plans a massive $23 billion investment to expand U.S. manufacturing with 10 new plants. The expansion is projected to generate 5,000 jo

Novartis (NVS) has announced a strategic plan to invest $23 billion over the next five years to upgrade its operations in the United States. This significant in

Shares of Novartis AG (NVS) fell 3.20% in mid-day trading on Apr 9. The stock reached an intraday low of $97.72, before recovering slightly to $98.70, down

Novartis shares experience a decline following tariff announcements impacting pharmaceutical imports. Wall Street analysts estimate a moderate upside po

Novartis (NVS) achieves accelerated FDA approval for Vanrafia, enhancing IgAN treatment options. Analyst price targets suggest a potential upside for Novart

Pharma warns EU of US exodus due to tariffs, risking billions in investment, demands policy change for competitiveness.

**media[588774]**

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

Union minister of commerce and industry Piyush Goyal’s remarks may have been slightly misdirected.

Novartis AG's plan to sell its 70.68% stake in Novartis India faces challenges due to market volatility impacting valuation. Despite strategic reviews and potential interest, fluctuations in stock prices and declining sales present hurdles in reaching a deal, with existing licensing agreements adding complexity.

**media[577816]**

**media[577814]**

(Bloomberg) -- This year’s unexpected demand for European stocks is helping to drive the region’s largest wave of block sales this century, with bankers anticipating more deals ahead.Most Read from BloombergThey Built a Secret Apartment in a Mall. Now the Mall Is Dying.Chicago Transit Faces ‘Doomsday Scenario,’ Regional Agency SaysLA Faces $1 Billion Budget Hole, Warns of Thousands of LayoffsNew York Subway Ditches MetroCard After 32 Years for Tap-And-GoDespite Cost-Cutting Moves, Trump Plans to

On March 20, 2025, Novartis AG (NVS) announced that its oral medication, Fabhalta® (iptacopan), has received approval from the U.S. Food and Drug Administratio